Literature DB >> 28961692

The Neuropsychology (Broadly Conceived) of Multiple System Atrophy, Progressive Supranuclear Palsy, and Corticobasal Degeneration.

Adam Gerstenecker1,2.   

Abstract

OBJECTIVE: To review the cognitive and behavioral features of the different atypical parkinsonian syndromes in which motor symptoms dominate early clinical symptomology: multiple systems atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). The impact of cognitive and behavioral deficits on quality of life, associations between neuropsychological and neuropsychiatric findings and brain imaging, and cognitive and behavioral symptom management are also discussed.
METHOD: A review of the available MSA, PSP, and CBD literature was conducted, with emphasis given to studies investigating the cognitive and behavioral features of the syndromes.
RESULTS: Although the three reviewed atypical parkinsonian syndromes share many similarities to each other and PD from a neuropsychological perspective, differences in prevalence and severity of cognitive impairment and patterns of performance on neuropsychological and neuropsychiatric measures exist in the research literature.
CONCLUSIONS: Cognitive and behavioral features are early and pervasive aspects of MSA, PSP, and CBD.
© The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Executive function; Fluency (verbal/nonverbal); Movement disorders; Parkinson's disease

Mesh:

Year:  2017        PMID: 28961692     DOI: 10.1093/arclin/acx093

Source DB:  PubMed          Journal:  Arch Clin Neuropsychol        ISSN: 0887-6177            Impact factor:   2.813


  7 in total

1.  Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.

Authors:  Gabriella Santangelo; Sofia Cuoco; Maria Teresa Pellecchia; Roberto Erro; Paolo Barone; Marina Picillo
Journal:  J Neurol       Date:  2018-09-03       Impact factor: 4.849

2.  Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson's disease.

Authors:  Eleonora Fiorenzato; Angelo Antonini; Valeria Camparini; Luca Weis; Carlo Semenza; Roberta Biundo
Journal:  J Neural Transm (Vienna)       Date:  2019-08-20       Impact factor: 3.575

3.  Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study.

Authors:  Marta F Pereira; Tim Buchanan; Günter U Höglinger; Marko Bogdanovic; George Tofaris; Simon Prangnell; Nagaraja Sarangmat; James J FitzGerald; Chrystalina A Antoniades
Journal:  BMJ Neurol Open       Date:  2022-01-21

4.  Co-Occurrence of Apathy and Impulsivity in Progressive Supranuclear Palsy.

Authors:  Zi Q Kok; Alexander G Murley; Timothy Rittman; James Rowe; Luca Passamonti
Journal:  Mov Disord Clin Pract       Date:  2021-09-16

5.  Optimization of cognitive assessment in Parkinsonisms by applying artificial intelligence to a comprehensive screening test.

Authors:  Paola Ortelli; Davide Ferrazzoli; Viviana Versace; Veronica Cian; Marianna Zarucchi; Anna Gusmeroli; Margherita Canesi; Giuseppe Frazzitta; Daniele Volpe; Lucia Ricciardi; Raffaele Nardone; Ingrid Ruffini; Leopold Saltuari; Luca Sebastianelli; Daniele Baranzini; Roberto Maestri
Journal:  NPJ Parkinsons Dis       Date:  2022-04-11

6.  Reduced phonemic fluency in progressive supranuclear palsy is due to dysfunction of dominant BA6.

Authors:  Valeria Isella; Daniele Licciardo; Francesca Ferri; Cinzia Crivellaro; Sabrina Morzenti; Ildebrando Appollonio; Carlo Ferrarese
Journal:  Front Aging Neurosci       Date:  2022-09-08       Impact factor: 5.702

7.  Atypical Initial Presentation of Painful Muscle Cramps in a Patient with Amyotrophic Lateral Sclerosis: A Case Report and Brief Review of the Literature.

Authors:  Aaron R Kuzel; Muhammad Uzair Lodhi; Intekhab Askari Syed; Mustafa Rahim
Journal:  Cureus       Date:  2017-11-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.